Triphasic vascular responses to bradykinin in the mesenteric resistance artery of the rat

Hideki Nawa, Hiromu Kawasaki, Akira Nakatsuma, Sachiko Isobe, Yuji Kurosaki

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The vascular effects of bradykinin were studied in rat perfused mesenteric vascular beds with active tone. Bolus injections of bradykinin (1-1000 pmol) but not des-Arg9-bradykinin (bradykinin B1 receptor agonist) induced triphasic vascular responses: the initial sharp vasodilation followed by transient vasoconstriction and subsequent gradual vasodilation. The triphasic vascular responses to bradykinin were abolished by FR 172357 (3-bromo-8-[2,6-dichloro-3-[N-[(E)-4-(N,N-dimethylcarbamoyl) cinnamidoacetyl]-N-methylamino]benzyloxy]-2-metylimidazo[1,2-a]pyridine) (bradykinin B2 receptor antagonist, 0.1 μM). Endothelium removal with sodium deoxycholate and Nw-nitro-L-arginine (300 μM) abolished the bradykinin-induced initial sharp vasodilation. Indomethacin (0.5 μM) and seratrodast (thromboxane A2 receptor antagonist, 0.5 and 5 μM) abolished the bradykinin-induced second vasoconstriction. The bradykinin-induced third vasodilation was abolished by capsaicin (1 μM) and calcitonin gene-related peptide (CGRP)-(8-37) (CGRP receptor antagonist, 0.5 μM). These findings suggest that the bradykinin-induced initial sharp vasodilation is endothelium dependent, that endogenous thromboxane A2 is involved in the second vasoconstriction, and that the third slow vasodilation is produced by activation of capsaicin-sensitive CGRP-containing nerves.

Original languageEnglish
Pages (from-to)105-113
Number of pages9
JournalEuropean Journal of Pharmacology
Volume433
Issue number1
DOIs
Publication statusPublished - Dec 14 2001

Fingerprint

Mesenteric Arteries
Bradykinin
Blood Vessels
Vasodilation
Vasoconstriction
seratrodast
Capsaicin
Endothelium
Bradykinin B1 Receptors
Calcitonin Gene-Related Peptide Receptors
Prostaglandin H2 Receptors Thromboxane A2
Thromboxane A2
Deoxycholic Acid
Calcitonin Gene-Related Peptide
Indomethacin
Arginine
Injections

Keywords

  • Bradykinin
  • CGRP (calcitonin gene-related peptide)
  • Endothelium dependent
  • Mesenteric resistance artery, (Rat)
  • Thromboxane A
  • Vasodilation

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Triphasic vascular responses to bradykinin in the mesenteric resistance artery of the rat. / Nawa, Hideki; Kawasaki, Hiromu; Nakatsuma, Akira; Isobe, Sachiko; Kurosaki, Yuji.

In: European Journal of Pharmacology, Vol. 433, No. 1, 14.12.2001, p. 105-113.

Research output: Contribution to journalArticle

Nawa, Hideki ; Kawasaki, Hiromu ; Nakatsuma, Akira ; Isobe, Sachiko ; Kurosaki, Yuji. / Triphasic vascular responses to bradykinin in the mesenteric resistance artery of the rat. In: European Journal of Pharmacology. 2001 ; Vol. 433, No. 1. pp. 105-113.
@article{7d4cd4ad89df4a88beb6e5d81efa7288,
title = "Triphasic vascular responses to bradykinin in the mesenteric resistance artery of the rat",
abstract = "The vascular effects of bradykinin were studied in rat perfused mesenteric vascular beds with active tone. Bolus injections of bradykinin (1-1000 pmol) but not des-Arg9-bradykinin (bradykinin B1 receptor agonist) induced triphasic vascular responses: the initial sharp vasodilation followed by transient vasoconstriction and subsequent gradual vasodilation. The triphasic vascular responses to bradykinin were abolished by FR 172357 (3-bromo-8-[2,6-dichloro-3-[N-[(E)-4-(N,N-dimethylcarbamoyl) cinnamidoacetyl]-N-methylamino]benzyloxy]-2-metylimidazo[1,2-a]pyridine) (bradykinin B2 receptor antagonist, 0.1 μM). Endothelium removal with sodium deoxycholate and Nw-nitro-L-arginine (300 μM) abolished the bradykinin-induced initial sharp vasodilation. Indomethacin (0.5 μM) and seratrodast (thromboxane A2 receptor antagonist, 0.5 and 5 μM) abolished the bradykinin-induced second vasoconstriction. The bradykinin-induced third vasodilation was abolished by capsaicin (1 μM) and calcitonin gene-related peptide (CGRP)-(8-37) (CGRP receptor antagonist, 0.5 μM). These findings suggest that the bradykinin-induced initial sharp vasodilation is endothelium dependent, that endogenous thromboxane A2 is involved in the second vasoconstriction, and that the third slow vasodilation is produced by activation of capsaicin-sensitive CGRP-containing nerves.",
keywords = "Bradykinin, CGRP (calcitonin gene-related peptide), Endothelium dependent, Mesenteric resistance artery, (Rat), Thromboxane A, Vasodilation",
author = "Hideki Nawa and Hiromu Kawasaki and Akira Nakatsuma and Sachiko Isobe and Yuji Kurosaki",
year = "2001",
month = "12",
day = "14",
doi = "10.1016/S0014-2999(01)01513-8",
language = "English",
volume = "433",
pages = "105--113",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Triphasic vascular responses to bradykinin in the mesenteric resistance artery of the rat

AU - Nawa, Hideki

AU - Kawasaki, Hiromu

AU - Nakatsuma, Akira

AU - Isobe, Sachiko

AU - Kurosaki, Yuji

PY - 2001/12/14

Y1 - 2001/12/14

N2 - The vascular effects of bradykinin were studied in rat perfused mesenteric vascular beds with active tone. Bolus injections of bradykinin (1-1000 pmol) but not des-Arg9-bradykinin (bradykinin B1 receptor agonist) induced triphasic vascular responses: the initial sharp vasodilation followed by transient vasoconstriction and subsequent gradual vasodilation. The triphasic vascular responses to bradykinin were abolished by FR 172357 (3-bromo-8-[2,6-dichloro-3-[N-[(E)-4-(N,N-dimethylcarbamoyl) cinnamidoacetyl]-N-methylamino]benzyloxy]-2-metylimidazo[1,2-a]pyridine) (bradykinin B2 receptor antagonist, 0.1 μM). Endothelium removal with sodium deoxycholate and Nw-nitro-L-arginine (300 μM) abolished the bradykinin-induced initial sharp vasodilation. Indomethacin (0.5 μM) and seratrodast (thromboxane A2 receptor antagonist, 0.5 and 5 μM) abolished the bradykinin-induced second vasoconstriction. The bradykinin-induced third vasodilation was abolished by capsaicin (1 μM) and calcitonin gene-related peptide (CGRP)-(8-37) (CGRP receptor antagonist, 0.5 μM). These findings suggest that the bradykinin-induced initial sharp vasodilation is endothelium dependent, that endogenous thromboxane A2 is involved in the second vasoconstriction, and that the third slow vasodilation is produced by activation of capsaicin-sensitive CGRP-containing nerves.

AB - The vascular effects of bradykinin were studied in rat perfused mesenteric vascular beds with active tone. Bolus injections of bradykinin (1-1000 pmol) but not des-Arg9-bradykinin (bradykinin B1 receptor agonist) induced triphasic vascular responses: the initial sharp vasodilation followed by transient vasoconstriction and subsequent gradual vasodilation. The triphasic vascular responses to bradykinin were abolished by FR 172357 (3-bromo-8-[2,6-dichloro-3-[N-[(E)-4-(N,N-dimethylcarbamoyl) cinnamidoacetyl]-N-methylamino]benzyloxy]-2-metylimidazo[1,2-a]pyridine) (bradykinin B2 receptor antagonist, 0.1 μM). Endothelium removal with sodium deoxycholate and Nw-nitro-L-arginine (300 μM) abolished the bradykinin-induced initial sharp vasodilation. Indomethacin (0.5 μM) and seratrodast (thromboxane A2 receptor antagonist, 0.5 and 5 μM) abolished the bradykinin-induced second vasoconstriction. The bradykinin-induced third vasodilation was abolished by capsaicin (1 μM) and calcitonin gene-related peptide (CGRP)-(8-37) (CGRP receptor antagonist, 0.5 μM). These findings suggest that the bradykinin-induced initial sharp vasodilation is endothelium dependent, that endogenous thromboxane A2 is involved in the second vasoconstriction, and that the third slow vasodilation is produced by activation of capsaicin-sensitive CGRP-containing nerves.

KW - Bradykinin

KW - CGRP (calcitonin gene-related peptide)

KW - Endothelium dependent

KW - Mesenteric resistance artery, (Rat)

KW - Thromboxane A

KW - Vasodilation

UR - http://www.scopus.com/inward/record.url?scp=0035861916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035861916&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(01)01513-8

DO - 10.1016/S0014-2999(01)01513-8

M3 - Article

C2 - 11755140

AN - SCOPUS:0035861916

VL - 433

SP - 105

EP - 113

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -